TREASURE trial
Key facts
- Where
- Maastricht, HollandiaSee the site
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Hollandia
- University Hospital MaastrichtMaastricht, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Maastricht
- Trial code
- EU 2022-503135-33-00
- Record updated
- 2023. július 28.
- Original description
The main-objective is to evaluate the effect of an angiotensin-converting-enzyme (ACE) inhibitor compared to care as usual (i.e. no medication) during a two-year open-labeled treatment period in women with asymptomatic heart failure (HF) on reversibility of aberrant cardiac remodeling in asymptomatic HF towards healthy values.Read full original descriptionShow less
Timely recovery after subclinical heart failure
The main-objective is to evaluate the effect of an angiotensin-converting-enzyme (ACE) inhibitor compared to care as usual (i.e. no medication) during a two-year open-labeled treatment period in women with asymptomatic heart failure (HF) on reversibility of aberrant cardiac remodeling in asymptomatic HF towards healthy values.
Inclusion: Women, aged 18 years and older; Heart failure stage-B or diastolic dysfunction; Premenopausal, with or without a history of preeclamptic pregnancy; ≥½ and ≤ 30 years after the (first) (complicated) pregnancy; Last delivery at least 6 months ago.
Exclusion: Already using antihypertensive medication; Women have the intention to pursue pregnancy within 2 years (as ACE inhibitors may be teratogenic); Auto-immune disease(s) prior to the (complicated) pregnancy; Chronic hypertension prior to the complicated pregnancy; Suffering diabetes mellitus, kidney failure (GFR<60 ml/min/1.73m2), pre-existent auto-immune disease and/or liver insufficiency; Systolic blood pressure of ≥180 mmHg and/or diastolic blood pressure of ≥110 mmHg; Breastfeeding during participation; Women who do not want themselves and/or their general practitioner and specialist(s) to be informed about the test results.